Clinical Review Methodology
Quick answer
Clinical Review Methodology for Peptides is reviewed as a Medriva hub utility resource. The practical takeaway is to separate what is supported by human evidence from what is still theoretical, commercial, or regulatory-dependent. Evidence grade: n/a. Readers should use this page to frame a clinician conversation, not to self-prescribe, source, dose, or combine peptides.
For current regulatory movement, shortage status, warning letters, and compounding policy, check the Peptide Tracker before relying on older summaries.
This page describes how Medriva Peptides sources, grades, and clinically reviews its content. It exists so that a clinician, a journalist, or a careful reader can verify the provenance of any claim on the site.
1. The 5-grade evidence scale
Every medical claim in body copy is graded using a 5-grade scale, inline next to the claim.
| Grade | Language we use | When we use it |
|---|---|---|
| Strong | "evidence is strong," "well-established" | Multiple phase 3 RCTs; FDA approval for the indication; society guideline recommendation |
| Moderate | "evidence is moderate," "supported by" | Multiple phase 2 trials, or one phase 3 + consistent observational data |
| Preliminary | "evidence is preliminary," "early data suggest" | Phase 1/2 trials, single trial, mixed results |
| Anecdotal | "anecdotal," "case reports," "lacks RCT support" | Pre-clinical (rodent / in vitro) data, case series, no controlled data |
| Unestablished | "dosing is not established," "no human dosing consensus" | Non-FDA-approved compound with no consensus protocol |
We never publish a claim that we cannot grade. We never promote "X works" without a grade.
2. Citation rules
- Profiles: ≥ 5 peer-reviewed references. FDA label cited where applicable.
- Comparisons: ≥ 8 peer-reviewed references.
- Pillars (essays): ≥ 25 peer-reviewed references.
- Use-case hubs: ≥ 8 references plus cross-links to every relevant profile.
- Daily news posts: ≥ 1 primary source (PubMed, FDA letter, official press release).
Citations are linked inline to peer-reviewed sources, official labels, regulatory documents, or society guidance. We do not invent PubMed IDs or DOIs. Claims that cannot be sourced are removed or rewritten before publication.
3. The two-tier clinical review pipeline
We run two lanes. The full lane applies to all evergreen pages. The spot-check lane applies to daily news — unless the post contains a dosing or efficacy claim, in which case it escalates to the full lane.
| Lane | Applies to | Process | SLA |
|---|---|---|---|
| Full | Profiles, comparisons, claims, use-case hubs, guides, pillars, cost, safety, regulatory, testing, persona, stack, journey, lifestyle | Writer draft → clinical reviewer (full checklist) → editor → publish | 3–5 working days (longer for pillars) |
| Spot-check | Daily news, briefs, social copy | Writer/AI-assisted draft → editor + same-day clinical spot-check → publish | Same day; escalate to Full on dosing/efficacy |
The escalation rule is non-negotiable.
4. The clinical reviewer checklist (full lane)
For every full-lane page, the reviewer attests in writing (in the CMS) that they have:
- Verified the page template is followed.
- Graded every medical claim using the 5-grade scale.
- Confirmed no banned claims are present.
- Confirmed no dosing for non-FDA-approved compounds is presented as a protocol.
- Checked every citation (resolves, no invented PubMed IDs, primary sources used for efficacy claims).
- Confirmed the FDA status disclosure is present and accurate.
- Confirmed the medical disclaimer is present.
- Confirmed the affiliate disclosure is present above the fold.
- Confirmed internal links meet the minimums (≥ 6 outgoing, ≥ 3 incoming).
- Flagged any residual risk in the sign-off comment.
- Confirmed no conflict of interest with any link on the page.
- Set the last-reviewed date and added their byline with credentials.
A reviewer may not sign off on their own draft (separation of duties).
5. The reviewer panel
Our clinical reviewers are licensed U.S. clinicians — MD, DO, PharmD, NP, or PA with prescribing authority — with verifiable experience in endocrinology, weight management, longevity medicine, sports medicine, dermatology, or pharmacy compounding.
Each reviewer:
- Holds an active, unrestricted license in at least one U.S. state.
- Has provided license number, NPI, CV, and a signed Independent Contractor Agreement.
- Has disclosed all financial relationships in the prior 24 months; no reviewer has any financial relationship with a Medriva affiliate partner.
- Has completed Medriva compliance training and passed a short quiz.
We do not name "an editorial team" — every byline on the site is a real, named, credentialed person.
6. Conflicts of interest
A reviewer may not review a page that links to a partner with which they have a financial relationship. A reviewer may not review a page authored by a writer with whom they have a recent collaboration outside Medriva. Conflicts are re-disclosed annually and ad hoc.
7. Updates and corrections
A "last reviewed" date appears on every page. Material changes — new evidence, new FDA status, new pricing — trigger a re-review within 5 business days. Factual errors are corrected with an inline note + a dated update log at the bottom of the page. Substantive corrections are emailed to subscribers if the error was the basis of a dispatched newsletter.
8. Records and retention
Every sign-off comment is retained with the page in the CMS for at least 5 years. A quarterly compliance audit samples 20 pages and re-validates reviewer sign-off. License verification is re-run annually.
9. What we do not do (the hard lines)
- We do not publish efficacy promises.
- We do not publish "typical dose" tables for non-FDA-approved compounds.
- We do not publish before/after imagery.
- We do not publish celebrity or influencer tie-ins.
- We do not publish real-person testimonials with photos, weight numbers, or specific outcomes.
- We do not promote RUO-marketed compounds to a "medical" audience; we describe the literature, never recommend.
10. How to verify a claim
If you want to verify a specific claim on the site:
- Find the claim on the page and open the inline citation attached to it.
- Click the citation; it should resolve to a peer-reviewed source on PubMed, a DOI on a publisher's site, an FDA label, or a society guideline.
- If the citation does not resolve, email corrections@medriva.com. We acknowledge within 2 business days.
- The page's "last reviewed" date shows when the page was last clinically reviewed.
11. Contact
- Methodology questions: editor@medriva.com
- Corrections: corrections@medriva.com
- Press: press@medriva.com
Frequently Asked Questions
What is the main takeaway on Clinical Review Methodology for Peptides?
The main takeaway is that Clinical Review Methodology for Peptides should be evaluated through evidence quality, safety signals, regulatory status, and clinical fit. Stronger claims need stronger human data and clear source support.
Is Clinical Review Methodology for Peptides medical advice?
No. This page is educational and is not a diagnosis, treatment plan, prescription, or dosing recommendation. Personal decisions should be made with a licensed clinician who understands your medical history.
What should I verify before acting on this topic?
Verify whether the compound or product is FDA-approved for the intended use, whether the evidence applies to your situation, whether there are contraindications or interactions, and whether the latest regulator updates change access or safety assumptions.
Where should I check for new peptide updates?
Use the Peptide Tracker for current FDA actions, warning letters, OIG oversight items, WADA updates, compounding policy, and pharmacy-oversight signals.
